● Recruiting

This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.

Condition: Parkinson Disease · Sponsor: iRegene Therapeutics Co., Ltd.

PhasePhase 1/Phase 2

Planned participants5

Who can joinAll sexes, 30 Years to 75 Years

Healthy volunteersNo

About this study

This is a phase 1/2 clinical study to evaluate the safety, tolerability, feasibility, and preliminary efficacy of NouvNeu001 in patients with advanced Parkinson's Disease.

This description comes directly from the study's public registry record.

Talk to the study team

Meng Cai, Ph.D · 0086-027-59337986 · caimeng@iregene.com

Jing Zhao, PhD · zhaojing@iregene.com

Always discuss trial participation with your own doctor first.

Locations (1)

Cornell University Weill Medical College

New York, New York, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07102342